Welcome!

News Feed Item

Inflammatory Bowel Diseases: World Drug Market 2013-2023

NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Inflammatory Bowel Diseases: World Drug Market 2013-2023

http://www.reportlinker.com/p0595028/Inflammatory-Bowel-Diseases-World-D...

Report Details

Medicines for bowel inflammation - you explore R&D and potential sales

What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.

Analysis of what shapes the IBD drugs industry and determines its potential

Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.

Forecasts to 2023 and other data show you commercial potentials

Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.

You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.

Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.

The following sections, then, show what you get in our new investigation.

Prospects for the world market and submarkets for IBD medications

Our report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:

• Aminosalicylates

• Antibiotics

• Corticosteroids

• Biologic therapies (biological drugs)

• Immunomodulators.

How will those colonic medicines perform? Which classes of lower-gut treatment will generate most money? There you assess prospects for revenue growth.

Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential for those intestinal medicines. See how you can benefit.

You also find revenue predictions for leading products.

Forecasts for IBD drugs - what outlooks for sales?

How will top drugs perform to 2023 at world level? Our report forecasts individual revenues of 14 products, including these:• Humira• Remicade• Asacol• Pentasa• Lialda• Tysabri• Xifaxan• Cimzia• Entocort.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our investigation also divides its overall IBD world forecast into geographical regions.

National markets for treating those gastrointestinal disorders

Developments worldwide expand the inflammatory bowel treatment market. Hear about the best revenue prospects.

In developed and developing countries, many opportunities for producers and sellers of those drugs will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:• US• Japan• Germany, France, UK, Italy, and Spain (EU5)• China, India, Brazil, and Russia (BRIC).

There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape.

Research and development - assess innovation, trends, and possibilities

What about R&D - pipelines for new drugs? You assess trends there, including for these agents:

• Interleukin (IL) inhibitors

• Cell-adhesion molecule (CAM) inhibitors

• TNF alpha inhibitors

• Stem cell therapies

• Immunomodulators

• Chemokine receptors

• Antioxidants and barrier function therapies.

That R&D explores many molecular pathways and targets. It holds promise. You hear about innovations there - developments and their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our new study explains, discussing issues to help your work.

Issues affecting manufacturing and selling of IBD treatments

Our report also shows you issues and events affecting that industry and market from 2013, including these:

• Nature of ulcerative colitis and Crohn's disease

• Aetiology and epidemiology of IBD

• Monoclonal antibodies (mAbs) as medications

• Delivery systems for agents

• Vaccines and alternative therapy

• Genotyping and improvements to treatments.

There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.

Companies leading that industry and 2017 market value

From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our study predicts the world market for IBD drugs will reach $9.6bn in 2017, and expand further to 2023.

Our work shows you what technologies, products, and organisations hold greatest potential. In particular, it investigates these companies:

• AbbVie

• Janssen Biotech

Warner Chilcott

• Shire Pharmaceuticals.

From 2013 there exist prospects for new drugs and overall sales growth. Our report shows you the possibilities, helping you stay ahead.

Eight ways Inflammatory Bowel Diseases: World Drug Market 2013-2023 helps you

To sum up, then, our research and analysis give you the following knowledge:• Revenue to 2023 of the world market for IBD medicines - discover that industry's overall sales potential• Revenues to 2023 for 5 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales• Revenues to 2023 for 14 products - find sales outlooks for top brands, seeing how they can compete and succeed• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks• Review of R&D - explore progress in research and development, finding technological and medical possibilities• Interviews with authorities on the field - discover debates and opinions to help you stay ahead• Competition and opportunities - investigate what shapes that market's future, including ways to develop business and succeed.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity for treating those gastrointestinal diseases. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.

Treatment of IBD - assess its potential now, seeing what you can gain

Our new study shows you data, trends, opportunities, and sales predictions for drugs treating inflammatory bowel disorders. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Inflammatory Bowel Disease Market Overview

1.2 Aims, Scope and Format of the Report

1.3 Chapter Outlines

1.4 Research and Analysis Methods

2. Introduction to the Inflammatory Bowel Disease Market

2.1 What is Inflammatory Bowel Disease (IBD)?

2.2 Are There Different Types of IBD?

2.3 Signs, Symptoms and Associated Conditions

2.4 What Causes Inflammatory Bowel Disease?

2.5 How Common is Inflammatory Bowel Disease?

3. Drug Treatments for Inflammatory Bowel Diseases

3.1 Can IBD be Cured?

3.2 What Are the Medications Used to Treat IBD?

3.2.1 Aminosalicylates - The Most Common Therapy

3.2.2 Corticosteroids - Limited in the Long-Run?

3.2.3 Immunomodulators - Slow to Act?

3.2.4 Monoclonal Antibodies - The Future?

3.2.5 Antibiotics - Do they Really Help?

3.3 Treatment Protocol

4. The World Inflammatory Bowel Disease Market, 2013-2023

4.1 The Inflammatory Bowel Disease Market in 2012: Domination of Biologics and Aminosalicylates

4.2 Forecast 2013-2023: Any Major Changes Expected?

4.3 Aminosalicylates Forecast 2013-2023: The Work-Horse of IBD Therapy

4.4 Antibiotics Forecast 2013-2023: Will They Still Be Relevant in a Decade?

4.5 Biologic Therapies Forecast 2013-2023: Main Driver of Growth

4.6 Corticosteroids Forecast 2013-2023: Continued Insignificance?

4.7 Immunomodulators Forecast 2013-2023

5. Leading National Markets, 2013-2023

5.1 IBD Drugs - Leading National Markets, 2012

5.2 The US IBD Drug Market, Revenues 2013-2023 - Leader of the Pack

5.2.1 Case Study: What is the Relative Contribution of Ulcerative Colitis and Crohn's Disease to Total IBD Spending in the US?

5.3 The Japanese IBD Drug Market, Revenues 2013-2023 - Tomorrow's Leader?

5.4 The EU-5 IBD Drug Markets, Revenues 2013-2023 - Europe's Growth Potential

5.5 IBD Drug Markets in BRIC Countries, Revenues 2013-2023 - Vast Potential for Sales

5.5.1 Brazil: Revenues 2013-2023

5.5.2 Russia: Revenues 2013-2023

5.5.3 India: Revenues 2013-2023

5.5.4 China: Revenues 2013-2023

6. Market Prospects for Leading IBD Drugs, 2013-2023

6.1 Humira (AbbVie) - The Leading Therapy

6.1.1Humira: Forecast and Analysis, 2013-2023

6.2 Remicade (Janssen Biotech) - A Worthy Challenger?

6.2.1Remicade: Forecast and Analysis, 2013-2023

6.3 Asacol (Warner Chilcott) - The Best Mesalazine Formulation?

6.3.1Asacol: Forecast and Analysis, 2013-2023

6.4 Pentasa (Shire USA) - When Will a Generic Substitute Arrive?

6.4.1 Pentasa: Forecast and Analysis, 2013-2023

6.5 Lialda (Shire USA) - What Potential for that Medication?

6.5.1 Lialda: Forecast and Analysis, 2013-2023

6.6 Tysabri (Elan Pharmaceuticals) - Will Side Effects Prove Too Much?

6.6.1 Tysabri: Forecast and Analysis, 2013-20236.7 Xifaxan (Salix Pharmaceuticals)

6.7.1 Xifaxan: Forecast and Analysis, 2013-20236.8 Cimzia (UCB Inc.) - Approved in Only a Handful of Countries

6.8.1 Cimzia: Forecast and Analysis, 2013-2023

6.9 Entocort (AstraZeneca) - Prominent Steroid Treatment

6.9.1 Entocort: Forecast and Analysis, 2013-2023

6.10 Neoral (Novartis) - A Widely Used Immunosuppressant

6.10.1 Neoral: Forecast and Analysis, 2013-2023

6.11 Medrol (Pfizer Inc.) - Another Leading Steroid

6.11.1 Medrol: Forecast and Analysis, 2013-2023

6.12 Canasa/Salofalk (Aptalis Pharmaceuticals) - A Slow Decline

6.12.1 Canasa/Salofalk: Forecast and Analysis, 2013-2023

6.13 Apriso (Salix Pharmaceuticals) - A Serious Challenger to Asacol?

6.13.1 Apriso: Forecast and Analysis, 2013-2023

6.14 Azulfidine (Pfizer Inc.) - What Scope for Revenue Growth?

6.14.1 Azulfidine: Forecast and Analysis, 2013-2023

7. The R&D Pipeline for Inflammatory Bowel Disease, 2013

7.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation

7.1.1 Profile: Vidofludimus (4SC)

7.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue

7.2.1 Profile: Etrolizumab (Roche)

7.3 TNF-? Inhibitors - A Tried and Tested Target

7.3.1 Profile: Ozoralizumab (Ablynx)

7.4 Stem Cell Therapies - Basis for a Cure?

7.4.1 Profile: Remestemcel-L (Osiris Therapeutics)

7.5 Janus Kinase (JAK) Inhibitors - More Targets to Hit

7.5.1 Profile: Tasocitinib (Pfizer)

7.6 Immunomodulators - Will They Live Up To the Hype?

7.6.1 Profile: ZP1848 (Zealand Pharma)

7.7 Chemokine Receptors - Potential Exists

7.7.1 Profile: Vercirnon (ChemoCentryx/GSK)

7.8 Antioxidants and Barrier Function

7.8.1 Profile: Tetomilast (Otsuka) - The Future of IBD Treatment?

8. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2013-2023

8.1 SWOT and STEP Analysis of the IBD Market

8.2 What Factors Will Drive the IBD Market?

8.2.1 Increasing Disease Incidence

8.2.2 Better Diagnosis

8.2.3 Nature of the Disease

8.2.4 Delivery Systems

8.2.5 Biological Drugs

8.2.6 Socioeconomic Costs of IBD

8.3 What Factors Will Restrain the Market?

8.3.1 Lack of Understanding of Disease Aetiology

8.3.2 Compliance

8.3.3 Limits of Biologics

8.3.4 A Cure or Vaccine

8.3.5 The Possible Development of Alternative Treatments

8.3.6 Surgery - When Other Options Fail

9. Leading Companies in the IBD Market, 2013

9.1 The Largest Companies by Revenue

9.2 AbbVie - The Leader in a Highly Profitable Area

9.3 Janssen Biotech - Tomorrow's Powerhouse?

9.4 Warner Chilcott - A Strong Competitor

9.5 Shire Pharmaceuticals - Still a Major Player in the Future?

10. Research Interviews

10.1 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan

10.1.1 On Antibiotics in Treating IBD

10.1.2 On the Emergence of Biologic Therapies

10.1.3 On IBD in the Pakistani Context

10.1.4 On Any Preventative Measures that Can Be Taken

10.2 Professor John Hermon-Taylor, King's College London

10.2.1 The Significance of MAP in Crohn's

10.2.2 Rising Incidence of IBD

10.2.3 Defining IBD

10.2.4 Timeframe of MAP Vaccine

10.2.5 Antibiotic Activity of Other Crohn's Treatments

10.2.6 Alternative Treatments

10.2.7 Ethics of Crohn's Drug Development

10.2.8 The Impact of a Vaccine on the Market

10.2.9 On Claims that MAP is Not Implicated in CD

10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney

10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology

10.3.2 IBD and HIV/AIDS

10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments

10.3.4 Potential Cure?

10.3.5 Remicade and MAP10.3.6 Genotyping

10.3.7 Crohn's vs. Colitis

10.3.8 Future Therapies

10.3.9 The Potential and Future of Myoconda

11. Conclusions

11.1 IBD Market to Expand from 2013 to 2023

11.2 Aminosalicylates and Other Non-Biologic Treatments

11.3 Biologic Treatments

11.4 Improvements Needed in IBD Treatments

11.5 Future IBD Treatments: R&D Efforts Look Promising

11.6 The IBD Sector: Looking to the Future with Confidence

List of Tables

Table 2.1 World Incidence Rates for IBD, 2013

Table 2.2 Geographical Variations in the Incidence of IBD, 2013

Table 3.1 Other Drug Types Used to Treat IBD, 2013

Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012

Table 4.2 Global IBD Drug Market Forecast ($m), 2012-2023

Table 4.3 Global IBD Drug Forecast by Drug Category ($m), 2012-2023

Table 4.4 Global IBD Drug Market Drivers and Restraints, 2012-2023

Table 4.5 Global Aminosalicylates Forecast ($m), 2012-2023

Table 4.6 Global Aminosalicylates Drivers and Restraints, 2012-2023

Table 4.7 Global Antibiotics Forecast ($m), 2012-2023

Table 4.8 Global Antibiotics Drivers and Restraints, 2012-2023

Table 4.9 Global Biologic Therapies Forecast ($m), 2012-2023

Table 4.10 Global Biologic Therapies Drivers and Restraints, 2012-2023

Table 4.11 Global Corticosteroid Forecast ($m), 2012-2023

Table 4.12 Global Corticosteroids Drivers and Restraints, 2012-2023

Table 4.13 Global Immunomodulators Forecast ($m), 2012-2023

Table 4.14 Global Immunomodulators Drivers and Restraints, 2012-2023

Table 5.1 Global IBD Drug Revenues by Geographical Segments ($m), 2012

Table 5.2 Global IBD Drug Market Forecasts by Country ($m), 2012-2023

Table 5.3 US IBD Drug Market Forecast ($m), 2012-2023

Table 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023

Table 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023

Table 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023

Table 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023

Table 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023

Table 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023

Table 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023

Table 6.1 Leading IBD Treatments by Revenue ($m), 2012

Table 6.2 Leading IBD Medicines: Revenue Forecasts ($m), 2012-2023

Table 6.3 World Humira Revenue Forecast ($m), 2012-2023

Table 6.4 Drivers and Restraints for Humira, 2012-2023

Table 6.5 World Remicade Revenue Forecast ($m), 2012-2023

Table 6.6 Drivers and Restraints for Remicade, 2012-2023

Table 6.7 World Asacol Revenue Forecast ($m), 2012-2023

Table 6.8 Drivers and Restraints for Asacol, 2012-2023

Table 6.9 World Pentasa Revenue Forecast ($m), 2012-2023

Table 6.10 Drivers and Restraints for Pentasa, 2012-2023

Table 6.11 World Lialda Revenue Forecast ($m), 2012-2023

Table 6.12 Drivers and Restraints for Lialda, 2012-2023

Table 6.13 World Tysabri Revenue Forecast ($m), 2012-2023

Table 6.14 Drivers and Restraints for Tysabri, 2012-2023

Table 6.15 World Xifaxan Revenue Forecast ($m), 2012-2023

Table 6.16 Drivers and Restraints for Xifaxan, 2012-2023

Table 6.17 World Cimzia Revenue Forecast ($m), 2012-2023

Table 6.18 Drivers and Restraints for Cimzia, 2012-2023

Table 6.19 World Entocort Revenue Forecast ($m), 2012-2023

Table 6.20 Drivers and Restraints for Entocort, 2012-2023

Table 6.21 World Neoral Revenue Forecast ($m), 2012-2023

Table 6.22 Drivers and Restraints for Neoral, 2012-2023

Table 6.23 World Medrol Revenue Forecast ($m), 2012-2023

Table 6.24 Drivers and Restraints for Medrol, 2012-2023

Table 6.25 World Canasa Revenue Forecast ($m), 2012-2023

Table 6.26 Drivers and Restraints for Canasa, 2012-2023

Table 6.27 World Apriso Revenue Forecast ($m), 2012-2023

Table 6.28 Drivers and Restraints for Apriso, 2012-2023

Table 6.29 World Azulfidine Revenue Forecast ($m), 2012-2023

Table 6.30 Drivers and Restraints for Azulfidine, 2012-2023

Table 7.1 Selected IL Inhibitors in Clinical Development, 2013

Table 7.2 Selected CAM Inhibitors in Clinical Development, 2013

Table 7.3 Selected TNF-Alfa Inhibitors in Clinical Development, 2013

Table 7.4 Selected Stem Cell Therapies in Clinical Development, 2013

Table 7.5 Selected Immunomodulators in Clinical Development, 2013

Table 7.6 Selected Chemokine Receptors in Clinical Development, 2013

Table 7.7 Selected Antioxidants and Barrier Function Therapies in Clinical Development, 2013

Table 8.1 SWOT Analysis of the World IBD Drug Market, 2012-2023

Table 8.2 STEP Analysis of the World IBD Drug Market, 2012-2023

Table 9.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2012

Table 9.2 AbbVie Revenues ($m) and Market Share (%), 2012

Table 9.3 Janssen Biotech Revenues ($m) and Market Share (%), 2012

Table 9.4 Warner Chilcott Revenues ($m) and Market Share (%), 2012

Table 9.5 Shire's Revenues ($m) and Market Share (%), 2012

Table 11.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Product Category, 2013, 2017, 2023

Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Geographical Regions, 2013, 2017, 2023

Table 11.3 Summary of IBD Market Drivers and Restraints, 2013-2023

List of Figures

Figure 3.1 Treatment Protocol for IBD, 2013

Figure 4.1 World IBD Drugs Market Shares by Product Type (%), 2012

Figure 4.2 Global IBD Drug Market Forecast ($m), 2012-2023

Figure 4.3 World IBD Drugs Market Shares by Product Type (%), 2023

Figure 4.4 Global Aminosalicylates Forecast ($m), 2012-2023

Figure 4.5 Global Antibiotics Forecast ($m), 2012-2023

Figure 4.6 Global Biologic Therapies Forecast ($m), 2012-2023

Figure 4.7 Global Corticosteroid Forecast ($m), 2012-2023

Figure 4.8 Global Immunomodulators Forecast ($m), 2012-2023

Figure 5.1 Global IBD Drug Market by Geographical Segments (%), 2012

Figure 5.2 Global IBD Drug Market by Geographical Segments (%), 2023

Figure 5.3 US IBD Drug Market Forecast ($m), 2012-2023

Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023

Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023

Figure 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023

Figure 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023

Figure 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023

Figure 6.1 World Humira Revenue Forecast ($m), 2012-2023

Figure 6.2 World Remicade Revenue Forecast ($m), 2012-2023

Figure 6.3 World Asacol Revenue Forecast ($m), 2012-2023

Figure 6.4 World Pentasa Revenue Forecast ($m), 2012-2023

Figure 6.5 World Lialda Revenue Forecast ($m), 2012-2023

Figure 6.6 World Tysabri Revenue Forecast ($m), 2012-2023

Figure 6.7 World Xifaxan Revenue Forecast ($m), 2012-2023

Figure 6.8 World Cimzia Revenue Forecast ($m), 2012-2023

Figure 6.9 World Entocort Revenue Forecast ($m), 2012-2023

Figure 6.10 World Neoral Revenue Forecast ($m), 2012-2023

Figure 6.11 World Medrol Revenue Forecast ($m), 2012-2023

Figure 6.12 World Canasa Revenue Forecast ($m), 2012-2023

Figure 6.13 World Apriso Revenue Forecast ($m), 2012-2023

Figure 6.14 World Azulfidine Revenue Forecast ($m), 2012-2023

Figure 9.1 Top 4 Companies for IBD Drugs: Market Shares (%), 2012

Companies Listed

4SC

Abbott Laboratories

AbbVie

Ablynx

Active Biotech

Aga Khan University Hospital

Ajinomoto Group

Amalyte Pharmaceuticals

Aptalis Pharmaceuticals

ARCA

AstraZeneca

Athersys

Atlantic Pharmaceuticals

Biogen Idec

Bristol-Myers Squibb

Cambridge Antibody Technology

Catabasis Pharmaceuticals

Celgene Cellular Therapies

Celltech Pharmaceuticals

Centocor Ortho Biotech

Centre for Digestive Diseases, Sydney

Centres for Disease Control and Prevention

ChemoCentryx

China Medical

Cosmo Pharmaceuticals

Crohn's and Colitis Foundation of America

Crohn's and Colitis Foundation of Canada

Elan Corporation

European Federation of Crohn's and Ulcerative Colitis Associations

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Giaconda

Giuliani

GlaxoSmithKline (GSK)

Harbor BioSciences

Hutchison MediPharma

InDex Pharmaceuticals

Isis Pharmaceuticals

Janssen Biotech

Johnson & Johnson

King's College London

Kyorin Pharmaceutical Co.

Lipid Therapeutics

Medarex

Merck & Co.

Mylan Pharmaceuticals

Neovacs

Novartis

Nycomed

Osiris Therapeutics

Otsuka Pharmaceutical Group

Palau Pharma

PDL BioPharma

Pfizer

Probiotic Therapy Research Centre, Sydney, Australia

Procter & Gamble Pharmaceuticals

Prometheus Laboratories

Roche

Salix Pharmaceuticals

Sanofi

Shire Pharmaceuticals Group

Sigmoid Pharma

Takeda

Teva Pharmaceutical Industries

TxCell

UCB

Warner Chilcott

World Gastroenterology Organisation (WGO)

Zealand Pharma

To order this report:Drug_and_Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2013-2023

__________________________

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
Regardless of what business you’re in, it’s increasingly a software-driven business. Consumers’ rising expectations for connected digital and physical experiences are driving what some are calling the "Customer Experience Challenge.” In his session at @DevOpsSummit at 20th Cloud Expo, Marco Morales, Director of Global Solutions at CollabNet, will discuss how organizations are increasingly adopting a discipline of Value Stream Mapping to ensure that the software they are producing is poised to ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
When NSA's digital armory was leaked, it was only a matter of time before the code was morphed into a ransom seeking worm. This talk, designed for C-level attendees, demonstrates a Live Hack of a virtual environment to show the ease in which any average user can leverage these tools and infiltrate their network environment. This session will include an overview of the Shadbrokers NSA leak situation.
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
SYS-CON Events announced today that DivvyCloud will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. DivvyCloud software enables organizations to achieve their cloud computing goals by simplifying and automating security, compliance and cost optimization of public and private cloud infrastructure. Using DivvyCloud, customers can leverage programmatic Bots to identify and remediate common cloud problems in rea...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
SYS-CON Events announced today that Tintri, Inc, a leading provider of enterprise cloud infrastructure, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Tintri offers an enterprise cloud platform built with public cloud-like web services and RESTful APIs. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds – to build agile development environments...